OraSure Technologies (OSUR)
(Delayed Data from NSDQ)
$4.10 USD
+0.08 (1.99%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $4.10 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.10 USD
+0.08 (1.99%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $4.10 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value A Growth D Momentum A VGM
Zacks News
Zacks.com featured highlights: Baxter International, Lantheus Holdings, OraSure Technologies, MAM Software Group and Teradyne
by Zacks Equity Research
Zacks.com featured highlights: Baxter International, Lantheus Holdings, OraSure Technologies, MAM Software Group and Teradyne
5 Top Efficient Stocks to Add to Your Portfolio
by Tirthankar Chakraborty
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns
Why OraSure (OSUR) Could Be an Impressive Growth Stock
by Zacks Equity Research
If you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider OraSure (OSUR).
Abbott Laboratories Agrees to Acquire Alere at Lower Price
by Zacks Equity Research
Abbott has agreed to pay $51 per common share to acquire Alere, a reduction from earlier deal of $56 per common share upon the completion of the transaction.
Zimmer Biomet (ZBH) Upgraded to Hold on Solid Prospects
by Zacks Equity Research
On Apr 7, leading musculoskeletal healthcare company Zimmer Biomet Holdings, Inc. (ZBH) was raised to a Zacks Rank #3 (Hold).
Medtronic Initiates Product Recall, A Drag on Neurosurgery
by Zacks Equity Research
Medtronic plc. (MDT) has initiated a voluntary product recall of all unused units of its StrataMR adjustable valves and shunts based on an increase in the product complaint rate.
VWR Corp Continues its Acquisition Spree with MESM Buyout
by Zacks Equity Research
VWR Corporation (VWR) recently acquired a global provider of laboratory and medical equipment and ancillary supplies to clinical trials, MESM Ltd.
Medtronic (MDT) Less-Invasive HVAD Pump Results Positive
by Zacks Equity Research
Medtronic plc (MDT), a leading name in medical device space, recently presented preliminary results from its HVAD LATERAL study.
Medtronic HVAD System Results Positive for Long-Term Therapy
by Zacks Equity Research
Medical device major Medtronic plc (MDT) recently released results of its ENDURANCE Supplemental trial in regard to HVAD System.
IDEXX Laboratories' CAG Revenues Solid, Competition Rife
by Zacks Equity Research
On Apr 5, we issued an updated research report on Delaware NJ-based IDEXX Laboratories, Inc. (IDXX).
Walgreens Boots (WBA) Meets Q2 Earnings, Retains EPS View
by Zacks Equity Research
Walgreens Boots Alliance, Inc. (WBA) reported adjusted earnings per share (EPS) of $1.36 in second-quarter fiscal 2017, up 6.1% year over year.
Walgreens, Prime Form Central Specialty & Mail Service Company
by Zacks Equity Research
Walgreens Boots Alliance (WBA), in a partnership with pharmacy benefit manager (PBM) Prime Therapeutics LLC, recently formed a combined central specialty pharmacy and mail services company AllianceRx .
NuVasive Receives FDA 510(k) Clearance in Cervical Spine
by Zacks Equity Research
NuVasive Inc. (NUVA) received the U.S. FDA's 510(K) clearance for one of its spine products.
Amedisys to Buy East Tennessee to Expand in Personal Care
by Zacks Equity Research
Amedisys Inc. (AMED) recently signed a definitive agreement to buy substantially all of the assets of a Knoxville, TN-based personal care provider, East Tennessee Personal Care Service.
Boston Scientific (BSX) Inks Agreement to Acquire Symetis SA
by Zacks Equity Research
Boston Scientific Corporation (BSX) recently signed a definitive agreement to acquire Switzerland-based Symetis SA for $435 million in up-front cash, in a bid to fortify its structural heart business in Europe.
Abbott's St Jude Buyout to Boost Business, Risks Remain
by Zacks Equity Research
On Mar 31, we updated our research report on medical device major, Abbott Laboratories (ABT).
Genomic Health's GPS Predicts Metastatic Prostate Cancer
by Zacks Equity Research
Genomic Health, Inc. (GHDX), a global cancer company, recently unveiled positive results regarding Oncotype DX Genomic Prostate Score (GPS).
NuVasive (NUVA) Gets FDA 510(k) Clearance for CoRoent System
by Zacks Equity Research
Leading medical device company NuVasive, Inc. (NUVA) recently announced the receipt of U.S. FDA 510(k) clearance for its CoRoent Small Interbody System.
QIAGEN Offers JAK2 Kit in US, Grows in Molecular Diagnostics
by Zacks Equity Research
QIAGEN N.V. (QGEN) launched ipsogen JAK2 RGQ PCR Kit in the U.S, following the Food and Drug Administration's (FDA) approval.
Integra LifeSciences Expands Cadence System Commercially
by Zacks Equity Research
Integra LifeSciences Holdings Corporation (IART), a global medical technology company, recently announced full commercial expansion of its Cadence Total Ankle System.
5 Biggest Winners from the Obamacare Replacement Bill Pushback
by Swarup Gupta
This setback was largely an outcome of the lack of consensus among various factions of the GOP.
Zacks Industry Outlook Highlights: Quidel, OraSure Technologies, ResMed, Inogen and Masimo
by Zacks Equity Research
Zacks Industry Outlook Highlights: Quidel, OraSure Technologies, ResMed, Inogen and Masimo
Obamacare Repeal Vote Looms: What Investors Need to Know
by Madeleine Johnson
Investors' eyes will be focused on Congress today, as the House is scheduled to vote on the American Healthcare Act (AHCA). Whether you think it???s "Obamacare Lite" or "dead on arrival" like Sen. Rand Paul, the AHCA has certainly made an impact on Wall Street, as well as the entire healthcare industry since its announcement.
OraSure Technologies (OSUR) In Focus: Stock Jumps 8.4%
by Zacks Equity Research
OraSure Technologies, Inc. (OSUR) moved big last session, as its shares jumped over 8% on the day.
Top 5 Efficient Stocks to Buy Right Now
by Tirthankar Chakraborty
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns.